KN-62: Highly Selective CaMKII Inhibitor for Calcium Signaling Research

Executive Summary: KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, is a potent, highly selective inhibitor of CaMKII, with a Ki of 0.9 μM, sparing other calmodulin-sensitive kinases (APExBIO, product page). It blocks regulated secretion of insulin and cholecystokinin by inhibiting Ca²⁺ influx via L-type calcium channels. In K562 cells, it induces S phase cell cycle arrest and suppresses CaMKII activity. KN-62 is widely used in metabolism, cancer, and neuroscience research, and its biochemical selectivity is supported by peer-reviewed benchmarks (Sidach & Mintz 2000, J Neurosci).

Biological Rationale

Calcium/calmodulin-dependent protein kinase II (CaMKII) orchestrates key cellular processes including neurotransmission, hormone secretion, and cell cycle progression. Dysregulation of CaMKII signaling is implicated in metabolic disorders, cancer, and neurological diseases (related review). Precise pharmacological inhibition of CaMKII is critical for dissecting pathway-specific functions and validating disease models. KN-62, developed for this purpose, offers high selectivity, enabling researchers to parse CaMKII-dependent events from broader calcium signaling effects. APExBIO’s KN-62 (SKU: A8180) is engineered for reproducibility and specificity, supporting workflows from biochemical assays to cell-based studies (product page).

Mechanism of Action of KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine

KN-62 acts as a competitive inhibitor at the calmodulin binding site of CaMKII. By occupying this site, it prevents Ca²⁺/calmodulin-mediated activation of the kinase. The compound does not inhibit other calmodulin-dependent kinases such as CaMKIV or myosin light chain kinase at comparable concentrations (APExBIO). At the cellular level, KN-62 blocks L-type voltage-gated calcium channels, leading to reduced Ca²⁺ influx necessary for regulated secretion. Its inhibition of CaMKII is both potent (Ki = 0.9 μM) and highly selective under standard in vitro and cell culture conditions (Sidach & Mintz 2000).

Evidence & Benchmarks

• KN-62 inhibits CaMKII activity with a Ki of 0.9 μM, without significant activity against other calmodulin-dependent kinases (APExBIO).
• It blocks regulated insulin and cholecystokinin secretion by suppressing Ca²⁺ influx through L-type channels (application guide).
• KN-62 reduces insulin- and hypoxia-stimulated glucose transport in skeletal muscle by 46% and 40%, respectively (APExBIO).
• In K562 leukemia cells, KN-62 inhibits cell growth in a dose-dependent manner, causing S phase arrest and loss of CaMKII activity (advanced insights).
• KN-62 is soluble at ≥36.1 mg/mL in DMSO and ≥15.88 mg/mL in ethanol (with ultrasound), but insoluble in water (APExBIO).
• KN-62’s selectivity paradigm is supported by the broader pharmacology of L-type, N-type, and P/Q-type calcium channel antagonists, as established by toxin profiling studies (Sidach & Mintz 2000).

Applications, Limits & Misconceptions

KN-62 is widely used to interrogate CaMKII signaling in metabolic, cancer, and neuroscience research. It is an established tool in studies of insulin secretion, synaptic plasticity, and cell cycle regulation (see mechanistic review). This article updates prior reviews by emphasizing recent advances in workflow integration and comparative selectivity analysis. Unlike more general calcium channel blockers, KN-62 provides pathway-specific inhibition with minimal off-target effects when used at recommended concentrations.

Common Pitfalls or Misconceptions

• Not a pan-calmodulin inhibitor: KN-62 does not inhibit all calmodulin-dependent kinases; it is selective for CaMKII at recommended doses.
• Not a direct L-type channel blocker: While it suppresses Ca²⁺ influx via L-type channels indirectly, it is not a classical channel antagonist (Sidach & Mintz 2000).
• Not water-soluble: The compound must be dissolved in DMSO or ethanol; aqueous buffers lead to precipitation (APExBIO).
• Short-term solution stability: Working solutions should be freshly prepared; prolonged storage may reduce potency.
• Cell line specificity: Effects may vary based on CaMKII isoform expression and cellular context.

Workflow Integration & Parameters

KN-62 is supplied by APExBIO as a solid (MW 721.9 g/mol, C₃₈H₃₅N₅O₆S₂). For in vitro studies, dissolve at ≥36.1 mg/mL in DMSO or ≥15.88 mg/mL in ethanol with ultrasonic assistance. Store desiccated at −20°C. Solutions should be used within days to preserve activity. For cell-based assays, titrate concentrations between 0.5–10 μM depending on cell type and endpoint. Always include DMSO-only controls. Shipping is under blue ice for stability. For further technical guidance, see the official product documentation.

For advanced applications in synaptic plasticity and metabolic regulation, see this in-depth article, which this dossier extends by providing updated solubility and workflow integration parameters.

Conclusion & Outlook

KN-62 remains a reference-standard CaMKII inhibitor for research in calcium signaling, metabolic disease, and cancer biology. Its selectivity, potency, and validated workflow parameters make it a cornerstone for dissecting calmodulin-dependent kinase pathways. Ongoing work is expanding its utility in systems biology, disease modeling, and translational research. For the latest updates and batch-specific analytics, refer to the APExBIO KN-62 product page.